Chinese Covid-19 vaccine V-01 enters phase-III trials in Philippines


An employee works at the Covid-19 vaccine trial production workshop at Livzon Pharmaceutical Group Inc in south China's Guangdong Province. - Xinhua

GUANGZHOU, Aug 30 (Xinhua): A recombinant Covid-19 fusion protein vaccine (V-01) developed and manufactured in China has been approved for phase-III clinical trials in the Philippines.

The V-01 vaccine was developed by the Institute of Biophysics under the Chinese Academy of Sciences and Livzon Pharmaceutical Group Inc. (LivzonBio) in south China's Guangdong Province.

Subscribe now and receive free sooka plan for 1 month. T&C applies.

Monthly Plan

RM13.90/month

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Aseanplus News

Two Japanese soldiers confirmed killed in training plane crash
Yingluck’s lawyers push for retrial in rice pledging case fight
Yingluck speaks out after court orders over US$305mil compensation
Vietnam's poultry industry faces major challenges amid weak value chain linkages
Belt and Road Initiative-backed industrial zone in Cambodia celebrates entry of over 200 enterprises
Laos moves to raise vaccine awareness, boost immunisation coverage
Bangladesh's interim government 'undermining' freedoms: rights group
PKR polls: Members will keep party 'fresh' no matter the result, says Rafizi
Thai ex-PM Yingluck ordered to pay US$305mil in damages over rice scheme
Stronger commitment urged to elevate Malay, Indonesian languages in Brunei

Others Also Read